Sporos Bioventures
Stephen Rubino, PhD, MBA, serves as the Chief Executive Officer of Sporos Bioventures since September 2022, leading initiatives to innovate the drug development process in oncology. With a robust background in the biotechnology industry, Rubino has held positions such as Chief Business Officer at Celyad Oncology and Entrepreneur In Residence at Fortress Biotech. Additionally, Rubino contributes to several boards, including Viracta Therapeutics and Sermonix Pharmaceuticals. A former Global Head at Novartis for Business Development & Licensing in the Cell & Gene Therapy Unit, Rubino has extensive experience in strategic planning and product commercialization, which began with a decade at Schering-Plough guiding global marketing efforts. Rubino holds a PhD in Virology from Cornell University and an MBA from Baruch College.
This person is not in any offices
Sporos Bioventures
Sporos is transforming knowledge into new hope for patients. With deep roots in Texas, connections within Texas Medical Center (TMC) and reach across the industry, the Company identifies novel disease mechanisms and strategically deploys talent, capital and access to operational resources to catalyze the development of breakthrough medicines. Sporos’ current pipeline is diversified across four entities and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease.